Certara (NASDAQ:CERT) Hits New 52-Week Low at $10.96

Certara, Inc. (NASDAQ:CERT)’s share price hit a new 52-week low during mid-day trading on Monday . The stock traded as low as $10.96 and last traded at $10.97, with a volume of 42993 shares changing hands. The stock had previously closed at $11.39.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on CERT shares. KeyCorp reduced their price objective on shares of Certara from $23.00 to $20.00 and set an “overweight” rating for the company in a report on Thursday, July 11th. Barclays lowered their price objective on Certara from $18.00 to $16.00 and set an “equal weight” rating on the stock in a research note on Friday, June 28th. UBS Group cut their target price on Certara from $20.00 to $16.00 and set a “neutral” rating for the company in a research report on Wednesday, August 7th. JMP Securities reiterated a “market perform” rating on shares of Certara in a research note on Wednesday, July 10th. Finally, Robert W. Baird reduced their target price on shares of Certara from $19.00 to $18.00 and set a “neutral” rating on the stock in a research note on Wednesday, August 7th. Seven equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to data from MarketBeat, Certara has a consensus rating of “Hold” and a consensus target price of $17.79.

Certara Stock Performance

The stock has a 50 day moving average price of $13.80 and a two-hundred day moving average price of $15.74. The company has a debt-to-equity ratio of 0.28, a current ratio of 2.61 and a quick ratio of 2.61. The company has a market capitalization of $1.77 billion, a price-to-earnings ratio of -28.23, a price-to-earnings-growth ratio of 5.31 and a beta of 1.50.

Certara (NASDAQ:CERT) last posted its quarterly earnings data on Tuesday, August 6th. The company reported $0.07 earnings per share for the quarter, missing the consensus estimate of $0.10 by ($0.03). Certara had a negative net margin of 21.64% and a positive return on equity of 3.03%. The company had revenue of $93.31 million during the quarter, compared to analyst estimates of $96.01 million. During the same quarter in the previous year, the business posted $0.10 EPS. The company’s revenue was up 3.2% compared to the same quarter last year. On average, analysts predict that Certara, Inc. will post 0.28 EPS for the current fiscal year.

Insider Buying and Selling at Certara

In related news, insider Leif E. Pedersen sold 51,224 shares of Certara stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $11.29, for a total value of $578,318.96. Following the completion of the sale, the insider now directly owns 99,704 shares in the company, valued at $1,125,658.16. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Corporate insiders own 2.39% of the company’s stock.

Hedge Funds Weigh In On Certara

Large investors have recently bought and sold shares of the business. Mubadala Investment Co PJSC bought a new stake in shares of Certara during the 4th quarter valued at $169,135,000. Wasatch Advisors LP lifted its stake in Certara by 23.4% in the first quarter. Wasatch Advisors LP now owns 4,924,845 shares of the company’s stock valued at $88,056,000 after buying an additional 932,598 shares during the period. Norges Bank bought a new position in Certara during the fourth quarter worth about $14,262,000. Daventry Group LP grew its position in shares of Certara by 153.0% during the 2nd quarter. Daventry Group LP now owns 1,308,572 shares of the company’s stock worth $18,124,000 after buying an additional 791,405 shares during the period. Finally, Geneva Capital Management LLC increased its stake in shares of Certara by 15.1% in the 1st quarter. Geneva Capital Management LLC now owns 4,404,199 shares of the company’s stock valued at $78,747,000 after acquiring an additional 579,349 shares during the last quarter. 73.96% of the stock is currently owned by institutional investors and hedge funds.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.